{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:53:08Z","timestamp":1776304388381,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72374113"],"award-info":[{"award-number":["72374113"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MOE (Ministry of Education in China) Project of Humanities and Social Sciences","award":["21YJAZH023"],"award-info":[{"award-number":["21YJAZH023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-024-20951-6","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T09:19:46Z","timestamp":1736932786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Jingyi","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maochun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsong","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"3","key":"20951_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"20951_CR2","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/cm9.0000000000002529","volume":"136","author":"C Li","year":"2023","unstructured":"Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, et al. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023;136(13):1583\u201390. https:\/\/doi.org\/10.1097\/cm9.0000000000002529.","journal-title":"Chin Med J (Engl)"},{"key":"20951_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.lungcan.2018.06.007","volume":"124","author":"S Andreas","year":"2018","unstructured":"Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, et al. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS). Lung Cancer. 2018;124:298\u2013309. https:\/\/doi.org\/10.1016\/j.lungcan.2018.06.007.","journal-title":"Lung Cancer"},{"issue":"5","key":"20951_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00432-016-2326-x","volume":"143","author":"MR Migliorino","year":"2017","unstructured":"Migliorino MR, Santo A, Romano G, Cortinovis D, Galetta D, Alabiso O, et al. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. J Cancer Res Clin Oncol. 2017;143(5):783\u201391. https:\/\/doi.org\/10.1007\/s00432-016-2326-x.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"20951_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.18553\/jmcp.2021.21216","volume":"28","author":"X Zhang","year":"2022","unstructured":"Zhang X, Beachler DC, Masters E, Liu F, Yang M, Dinh J, et al. Health care resource utilization and costs associated with advanced or metastatic non-small cell lung cancer in the United States. J Manag Care Spec Pharm. 2022;28(2):255\u201365. https:\/\/doi.org\/10.18553\/jmcp.2021.21216.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"20951_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.21147\/j.issn.1000-9604.2021.01.09","volume":"33","author":"C Liu","year":"2021","unstructured":"Liu C, Shi J, Wang H, Yan X, Wang L, Ren J, et al. Population-level economic burden of lung cancer in China: Provisional prevalence-based estimations, 2017\u20132030. Chin J Cancer Res. 2021;33(1):79\u201392. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.01.09.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"20951_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12962-021-00306-3","volume":"19","author":"X Zhang","year":"2021","unstructured":"Zhang X, Shi JF, Liu GX, Ren JS, Guo LW, Huang WD, et al. Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey. Cost Eff Resour Alloc. 2021;19(1):53. https:\/\/doi.org\/10.1186\/s12962-021-00306-3.","journal-title":"Cost Eff Resour Alloc"},{"issue":"8","key":"20951_CR8","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1002\/cam4.3845","volume":"10","author":"D Zhu","year":"2021","unstructured":"Zhu D, Shi X, Nicholas S, Ma Y, He P. Estimated annual prevalence, medical service utilization and direct costs of lung cancer in urban China. Cancer Med. 2021;10(8):2914\u201323. https:\/\/doi.org\/10.1002\/cam4.3845.","journal-title":"Cancer Med"},{"issue":"1","key":"20951_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1186\/s12885-021-09030-w","volume":"21","author":"CY Sun","year":"2021","unstructured":"Sun CY, Shi JF, Fu WQ, Zhang X, Liu GX, Chen WQ, et al. Catastrophic health expenditure and its determinants in households with lung cancer patients in China: a retrospective cohort study. BMC Cancer. 2021;21(1):1323. https:\/\/doi.org\/10.1186\/s12885-021-09030-w.","journal-title":"BMC Cancer"},{"issue":"8","key":"20951_CR10","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1007\/s00432-022-04258-w","volume":"149","author":"Y Yang","year":"2023","unstructured":"Yang Y, Xia Y, Su C, Chen J, Long E, Zhang H, et al. Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China. J Cancer Res Clin Oncol. 2023;149(8):4205\u201314. https:\/\/doi.org\/10.1007\/s00432-022-04258-w.","journal-title":"J Cancer Res Clin Oncol"},{"key":"20951_CR11","unstructured":"The Global Health Observatory, World Health Organization. Universal Health Coverage. 2021. https:\/\/www.who.int\/data\/gho\/data\/themes\/universal-health-coverage. Accessed 16 May 2023."},{"issue":"6","key":"20951_CR12","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/bcp.12566","volume":"79","author":"PG Mol","year":"2015","unstructured":"Mol PG, Arnardottir AH, Straus SM, de Graeff PA, Haaijer-Ruskamp FM, Quik EH, et al. Understanding drug preferences, different perspectives. Br J Clin Pharmacol. 2015;79(6):978\u201387. https:\/\/doi.org\/10.1111\/bcp.12566.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"20951_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.healthpol.2019.05.013","volume":"123","author":"C Cuadrado","year":"2019","unstructured":"Cuadrado C, Crispi F, Libuy M, Marchildon G, Cid C. National Health Insurance: a conceptual framework from conflicting typologies. Health Policy. 2019;123(7):621\u20139. https:\/\/doi.org\/10.1016\/j.healthpol.2019.05.013.","journal-title":"Health Policy"},{"key":"20951_CR14","unstructured":"Evidence to Policy and Impact Unit, Research for Health Department Science Division, World Health Organization. Evidence, policy, impact: WHO guide for evidence-informed decision-making. 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240039872. Accessed 21 June 2023."},{"issue":"3","key":"20951_CR15","doi-asserted-by":"publisher","first-page":"e002087","DOI":"10.1136\/bmjgh-2019-002087","volume":"5","author":"W Tao","year":"2020","unstructured":"Tao W, Zeng Z, Dang H, Li P, Chuong L, Yue D, et al. Towards universal health coverage: achievements and challenges of 10 years of healthcare reform in China. BMJ Glob Health. 2020;5(3):e002087. https:\/\/doi.org\/10.1136\/bmjgh-2019-002087.","journal-title":"BMJ Glob Health"},{"issue":"2","key":"20951_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5582\/bst.2020.01015","volume":"14","author":"J Lin","year":"2020","unstructured":"Lin J, Zhou J, Wang L. Health care reform in China from the perspective of physicians. Biosci Trends. 2020;14(2):151\u201355. https:\/\/doi.org\/10.5582\/bst.2020.01015.","journal-title":"Biosci Trends"},{"issue":"1","key":"20951_CR17","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1186\/s12889-021-11947-7","volume":"21","author":"J Geng","year":"2021","unstructured":"Geng J, Chen X, Shi J, Bao H, Chen Q, Yu H. Assessment of the satisfaction with public health insurance programs by patients with chronic diseases in China: a structural equation modeling approach. BMC Public Health. 2021;21(1):1886. https:\/\/doi.org\/10.1186\/s12889-021-11947-7.","journal-title":"BMC Public Health"},{"key":"20951_CR18","doi-asserted-by":"publisher","first-page":"1176200","DOI":"10.3389\/fpubh.2023.1176200","volume":"11","author":"I Jakab","year":"2023","unstructured":"Jakab I, Dimitrova M, Hou\u00ffez F, Bereczky T, F\u00f6v\u00e9nyes M, Maravic Z, et al. Recommendations for patient involvement in health technology assessment in Central and Eastern European countries. Front Public Health. 2023;11:1176200. https:\/\/doi.org\/10.3389\/fpubh.2023.1176200.","journal-title":"Front Public Health"},{"issue":"2","key":"20951_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40271-019-00408-4","volume":"13","author":"JC Bouvy","year":"2020","unstructured":"Bouvy JC, Cowie L, Lovett R, Morrison D, Livingstone H, Crabb N. Use of patient preference studies in HTA decision making: a NICE perspective. Patient. 2020;13(2):145\u20139. https:\/\/doi.org\/10.1007\/s40271-019-00408-4.","journal-title":"Patient"},{"issue":"6","key":"20951_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jval.2016.04.006","volume":"19","author":"AC M\u00fchlbacher","year":"2016","unstructured":"M\u00fchlbacher AC, Juhnke C, Beyer AR, Garner S. Patient-focused benefit-risk analysis to inform regulatory decisions: the European Union perspective. Value Health. 2016;19(6):734\u201340. https:\/\/doi.org\/10.1016\/j.jval.2016.04.006.","journal-title":"Value Health"},{"issue":"6","key":"20951_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jval.2016.04.008","volume":"19","author":"FR Johnson","year":"2016","unstructured":"Johnson FR, Zhou M. Patient preferences in regulatory benefit-risk assessments: a US perspective. Value Health. 2016;19(6):741\u20135. https:\/\/doi.org\/10.1016\/j.jval.2016.04.008.","journal-title":"Value Health"},{"issue":"5","key":"20951_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10198-022-01512-3","volume":"24","author":"K Manipis","year":"2023","unstructured":"Manipis K, Mulhern B, Haywood P, Viney R, Goodall S. Estimating the willingness-to-pay to avoid the consequences of foodborne illnesses: a discrete choice experiment. Eur J Health Econ. 2023;24(5):831\u201352. https:\/\/doi.org\/10.1007\/s10198-022-01512-3.","journal-title":"Eur J Health Econ"},{"issue":"11","key":"20951_CR23","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41431-021-00874-1","volume":"29","author":"I Goranitis","year":"2021","unstructured":"Goranitis I, Best S, Christodoulou J, Boughtwood T, Stark Z. Preferences and values for rapid genomic testing in critically ill infants and children: a discrete choice experiment. Eur J Hum Genet. 2021;29(11):1645\u201353. https:\/\/doi.org\/10.1038\/s41431-021-00874-1.","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"20951_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/jep.13095","volume":"25","author":"I Sever","year":"2019","unstructured":"Sever I, Verbi\u010d M, Sever EK. Estimating willingness-to-pay for health care: a discrete choice experiment accounting for non-attendance to the cost attribute. J Eval Clin Pract. 2019;25(5):843\u20139. https:\/\/doi.org\/10.1111\/jep.13095.","journal-title":"J Eval Clin Pract"},{"issue":"9","key":"20951_CR25","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jval.2019.04.1924","volume":"22","author":"EW de Bekker-Grob","year":"2019","unstructured":"de Bekker-Grob EW, Swait JD, Kassahun HT, Bliemer MCJ, Jonker MF, Veldwijk J, et al. Are healthcare choices predictable? The impact of discrete choice experiment designs and models. Value Health. 2019;22(9):1050\u201362. https:\/\/doi.org\/10.1016\/j.jval.2019.04.1924.","journal-title":"Value Health"},{"key":"20951_CR26","doi-asserted-by":"crossref","unstructured":"Feng Z, Meng J, Sun Y, Xie T, Lu W, Wang G et al. Assessment of patients\u2019 preferences for new anticancer drugs in China: a best-worst discrete choice experiment on three common cancer types. BMJ Open 2023; 13(6):e072469. https:\/\/doi.org\/0.1136\/bmjopen-2023-072469.","DOI":"10.1136\/bmjopen-2023-072469"},{"issue":"9","key":"20951_CR27","doi-asserted-by":"publisher","first-page":"e038051","DOI":"10.1136\/bmjopen-2020-038051","volume":"10","author":"J Geng","year":"2020","unstructured":"Geng J, Chen X, Bao H, Qian D, Shao Y, Yu H. Patients\u2019 preferences for health insurance coverage of new technologies for treating chronic diseases in China: a discrete choice experiment. BMJ Open. 2020;10(9):e038051. https:\/\/doi.org\/10.1136\/bmjopen-2020-038051.","journal-title":"BMJ Open"},{"key":"20951_CR28","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.2147\/PPA.S224529","volume":"13","author":"H Sun","year":"2019","unstructured":"Sun H, Wang H, Xu N, Li J, Shi J, Zhou N, et al. Patient preferences for chemotherapy in the treatment of non-small cell lung cancer: a multicenter discrete choice experiment (DCE) study in China. Patient Prefer Adherence. 2019;13:1701\u20139. https:\/\/doi.org\/10.2147\/PPA.S224529.","journal-title":"Patient Prefer Adherence"},{"key":"20951_CR29","doi-asserted-by":"publisher","first-page":"697711","DOI":"10.3389\/fphar.2021.697711","volume":"12","author":"Y Sugitani","year":"2021","unstructured":"Sugitani Y, Ito K, Ono S. Patient preferences for attributes of chemotherapy for lung cancer: discrete choice experiment study in Japan. Front Pharmacol. 2021;12:697711. https:\/\/doi.org\/10.3389\/fphar.2021.697711.","journal-title":"Front Pharmacol"},{"key":"20951_CR30","doi-asserted-by":"publisher","first-page":"653450","DOI":"10.3389\/fpubh.2021.653450","volume":"9","author":"F Liu","year":"2021","unstructured":"Liu F, Hu H, Wang J, Chen Y, Hui S, Hu M. A study of patient preferences for the treatment of non-small cell lung cancer in Western China: a discrete-choice experiment. Front Public Health. 2021;9:653450. https:\/\/doi.org\/10.3389\/fpubh.2021.653450.","journal-title":"Front Public Health"},{"key":"20951_CR31","doi-asserted-by":"publisher","unstructured":"Devlin N, Finch AP, Parkin D. Guidance to users of EQ-5D-5L value sets. In: Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide. Springer 2022;213\u2009\u2013\u200933. https:\/\/doi.org\/10.1007\/978-3-030-89289-0_5","DOI":"10.1007\/978-3-030-89289-0_5"},{"key":"20951_CR32","volume-title":"Getting started with conjoint analysis: strategies for product design and pricing research","author":"BK Orme","year":"2010","unstructured":"Orme BK. Getting started with conjoint analysis: strategies for product design and pricing research. 2nd ed. Madison, WI: Research; 2010.","edition":"2"},{"key":"20951_CR33","doi-asserted-by":"publisher","first-page":"100436","DOI":"10.1016\/j.jocm.2023.100436","volume":"49","author":"SY Assele","year":"2023","unstructured":"Assele SY, Meulders M, Vandebroek M. Sample size selection for discrete choice experiments using design features. J Choice Model. 2023;49:100436. https:\/\/doi.org\/10.1016\/j.jocm.2023.100436.","journal-title":"J Choice Model"},{"issue":"4","key":"20951_CR34","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00520-017-3944-9","volume":"26","author":"A Herrmann","year":"2018","unstructured":"Herrmann A, Sanson-Fisher R, Hall A, Wall L, Zdenkowski N, Waller A. A discrete choice experiment to assess cancer patients\u2019 preferences for when and how to make treatment decisions. Support Care Cancer. 2018;26(4):1215\u201320. https:\/\/doi.org\/10.1007\/s00520-017-3944-9.","journal-title":"Support Care Cancer"},{"issue":"3","key":"20951_CR35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1536867X0700700306","volume":"7","author":"AR Hole","year":"2007","unstructured":"Hole AR. Fitting mixed logit models by using maximum simulated likelihood. Stata J. 2007;7(3):388\u2013401.","journal-title":"Stata J"},{"issue":"10","key":"20951_CR36","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/hec.984","volume":"14","author":"M Bech","year":"2005","unstructured":"Bech M, Gyrd-Hansen D. Effects coding in discrete choice experiments. Health Econ. 2005;14(10):1079\u201383. https:\/\/doi.org\/10.1002\/hec.984.","journal-title":"Health Econ"},{"issue":"8","key":"20951_CR37","doi-asserted-by":"publisher","first-page":"488","DOI":"10.15171\/ijhpm.2019.29","volume":"8","author":"A Kazemi Karyani","year":"2019","unstructured":"Kazemi Karyani A, Akbari Sari A, Woldemichael A. Eliciting preferences for health insurance in Iran using discrete choice experiment analysis. Int J Health Policy Manag. 2019;8(8):488\u201397. https:\/\/doi.org\/10.15171\/ijhpm.2019.29.","journal-title":"Int J Health Policy Manag"},{"issue":"2","key":"20951_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/gim.2017.93","volume":"20","author":"MA Lewis","year":"2018","unstructured":"Lewis MA, Stine A, Paquin RS, Mansfield C, Wood D, Rini C, et al. Parental preferences toward genomic sequencing for non-medically actionable conditions in children: a discrete-choice experiment. Genet Med. 2018;20(2):181\u20139. https:\/\/doi.org\/10.1038\/gim.2017.93.","journal-title":"Genet Med"},{"issue":"2","key":"20951_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semradonc.2021.11.003","volume":"32","author":"IM Bumanlag","year":"2022","unstructured":"Bumanlag IM, Jaoude JA, Rooney MK, Taniguchi CM, Ludmir EB. Exclusion of older adults from cncer clinical trials: review of the literature and future recommendations. Semin Radiat Oncol. 2022;32(2):125\u201334. https:\/\/doi.org\/10.1016\/j.semradonc.2021.11.003.","journal-title":"Semin Radiat Oncol"},{"issue":"8","key":"20951_CR40","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jval.2020.04.1831","volume":"23","author":"DJ Mott","year":"2020","unstructured":"Mott DJ, Chami N, Tervonen T. Reporting quality of marginal rates of substitution in discrete choice experiments that elicit patient preferences. Value Health. 2020;23(8):979\u201384. https:\/\/doi.org\/10.1016\/j.jval.2020.04.1831.","journal-title":"Value Health"},{"issue":"8","key":"20951_CR41","doi-asserted-by":"publisher","first-page":"e066157","DOI":"10.1136\/bmjopen-2022-066157","volume":"13","author":"D Boyers","year":"2023","unstructured":"Boyers D, Kilonzo M, Davidson T, Cooper D, Wardle J, Bhal K, et al. Patient preferences for stress urinary incontinence treatments: a discrete choice experiment. BMJ Open. 2023;13(8):e066157. https:\/\/doi.org\/10.1136\/bmjopen-2022-066157.","journal-title":"BMJ Open"},{"key":"20951_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1472-6963-12-159","volume":"12","author":"PJ Robyn","year":"2012","unstructured":"Robyn PJ, Barnighausen T, Souares A, Savadogo G, Bicaba B, Sie A, et al. Health worker preferences for community-based health insurance payment mechanisms: a discrete choice experiment. BMC Health Serv Res. 2012;12:159. https:\/\/doi.org\/10.1186\/1472-6963-12-159.","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"20951_CR43","doi-asserted-by":"publisher","first-page":"e053270","DOI":"10.1136\/bmjopen-2021-053270","volume":"11","author":"X Yu","year":"2021","unstructured":"Yu X, Bao H, Shi J, Yuan X, Qian L, Feng Z, et al. Preferences for healthcare services among hypertension patients in China: a discrete choice experiment. BMJ Open. 2021;11(12):e053270. https:\/\/doi.org\/10.1136\/bmjopen-2021-053270.","journal-title":"BMJ Open"},{"issue":"2","key":"20951_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jval.2022.12.004","volume":"26","author":"JFP Bridges","year":"2023","unstructured":"Bridges JFP, de Bekker-Grob EW, Hauber B, Heidenreich S, Janssen E, Bast A, et al. A roadmap for increasing the usefulness and impact of patient-preference studies in decision making in health: a good practices report of an ISPOR task force. Value Health. 2023;26(2):153\u201362. https:\/\/doi.org\/10.1016\/j.jval.2022.12.004.","journal-title":"Value Health"},{"issue":"2","key":"20951_CR45","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1200\/op.20.00692","volume":"17","author":"BHL Goulart","year":"2021","unstructured":"Goulart BHL, Unger JM, Chennupati S, Fedorenko CR, Ramsey SD. Out-of-pocket costs for tyrosine kinase inhibitors and patient outcomes in EGFR- and ALK-Positive advanced non-small-cell lung cancer. JCO Oncol Pract. 2021;17(2):e130\u20139. https:\/\/doi.org\/10.1200\/op.20.00692.","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"20951_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-022-01198-8","volume":"41","author":"S Jiang","year":"2023","unstructured":"Jiang S, Ren R, Gu Y, Jeet V, Liu P, Li S. Patient preferences in targeted pharmacotherapy for cancers: a systematic review of discrete choice experiments. PharmacoEconomics. 2023;41(1):43\u201357. https:\/\/doi.org\/10.1007\/s40273-022-01198-8.","journal-title":"PharmacoEconomics"},{"key":"20951_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/ppa.s338840","volume":"16","author":"C Yong","year":"2022","unstructured":"Yong C, Cambron-Mellott MJ, Seal B, Will O, Maculaitis MC, Clapp K, et al. Patient and caregiver preferences for first-line treatments of metastatic non-small cell lung cancer: a discrete choice experiment. Patient Prefer Adherence. 2022;16:123\u201335. https:\/\/doi.org\/10.2147\/ppa.s338840.","journal-title":"Patient Prefer Adherence"},{"key":"20951_CR48","doi-asserted-by":"publisher","first-page":"921093","DOI":"10.3389\/fpubh.2022.921093","volume":"10","author":"H Zhu","year":"2022","unstructured":"Zhu H, Zhu J, Zhou Y, Shan L, Li C, Cui Y, et al. Impact of the national reimbursement drug list negotiation policy on accessibility of anticancer drugs in China: an interrupted time series study. Front Public Health. 2022;10:921093. https:\/\/doi.org\/10.3389\/fpubh.2022.921093.","journal-title":"Front Public Health"},{"issue":"8","key":"20951_CR49","doi-asserted-by":"publisher","first-page":"e2225973","DOI":"10.1001\/jamanetworkopen.2022.25973","volume":"5","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, et al. Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA Netw Open. 2022;5(8):e2225973. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.25973.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"20951_CR50","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamainternmed.2020.8588","volume":"181","author":"DE Meyers","year":"2021","unstructured":"Meyers DE, Jenei K, Chisamore TM, Gyawali B. Evaluation of the clinical benefit of cancer drugs submitted for reimbursement recommendation decisions in Canada. JAMA Intern Med. 2021;181(4):499\u2013508. https:\/\/doi.org\/10.1001\/jamainternmed.2020.8588.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"20951_CR51","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/cncr.32455","volume":"126","author":"AJN Raymakers","year":"2020","unstructured":"Raymakers AJN, Regier DA, Peacock SJ. Health-related quality of life in oncology drug reimbursement submissions in Canada: a review of submissions to the pan-canadian oncology drug review. Cancer. 2020;126(1):148\u201355. https:\/\/doi.org\/10.1002\/cncr.32455.","journal-title":"Cancer"},{"key":"20951_CR52","doi-asserted-by":"publisher","first-page":"j4530","DOI":"10.1136\/bmj.j4530","volume":"359","author":"C Davis","year":"2017","unstructured":"Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017;359:j4530. https:\/\/doi.org\/10.1136\/bmj.j4530.","journal-title":"BMJ"},{"issue":"8","key":"20951_CR53","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40261-023-01285-4","volume":"43","author":"G Chauca Strand","year":"2023","unstructured":"Chauca Strand G, Johansson N, Jakobsson N, Bonander C, Svensson M. Cancer drugs reimbursed with limited evidence on overall survival and quality of life: do follow-up studies confirm patient benefits? Clin Drug Investig. 2023;43(8):621\u201333. https:\/\/doi.org\/10.1007\/s40261-023-01285-4.","journal-title":"Clin Drug Investig"},{"key":"20951_CR54","unstructured":"National Development and Reform Commission of the People\u2019s Republic of China. https:\/\/www.ndrc.gov.cn\/fggz\/jjyxtj\/dfjjyx\/202302\/t20230228_1350032_ext.html (2023). Acccessed 20 Aug 2023."},{"issue":"8","key":"20951_CR55","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s10198-021-01335-8","volume":"22","author":"MM Pourrahmat","year":"2021","unstructured":"Pourrahmat MM, Kim A, Kansal AR, Hux M, Pushkarna D, Fazeli MS, et al. Health state utility values by cancer stage: a systematic literature review. Eur J Health Econ. 2021;22(8):1275\u201388. https:\/\/doi.org\/10.1007\/s10198-021-01335-8.","journal-title":"Eur J Health Econ"},{"issue":"8","key":"20951_CR56","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/jto.0b013e318299243b","volume":"8","author":"C Chouaid","year":"2013","unstructured":"Chouaid C, Agulnik J, Goker E, Herder GJ, Lester JF, Vansteenkiste J, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8(8):997\u20131003. https:\/\/doi.org\/10.1097\/jto.0b013e318299243b.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"20951_CR57","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/cncr.29232","volume":"121","author":"KM Kenzik","year":"2015","unstructured":"Kenzik KM, Martin MY, Fouad MN, Pisu M. Health-related quality of life in lung cancer survivors: latent class and latent transition analysis. Cancer. 2015;121(9):1520\u20138. https:\/\/doi.org\/10.1002\/cncr.29232.","journal-title":"Cancer"},{"issue":"2","key":"20951_CR58","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/cancers14020398","volume":"14","author":"D Redondo-S\u00e1nchez","year":"2022","unstructured":"Redondo-S\u00e1nchez D, Petrova D, Rodr\u00edguez-Barranco M, Fern\u00e1ndez-Navarro P, Jim\u00e9nez-Mole\u00f3n JJ, S\u00e1nchez MJ. Socio-economic inequalities in lung cancer outcomes: an overview of systematic reviews. Cancers (Basel). 2022;14(2):398. https:\/\/doi.org\/10.3390\/cancers14020398.","journal-title":"Cancers (Basel)"},{"key":"20951_CR59","doi-asserted-by":"crossref","unstructured":"Selby JV, Whitlock EP, Sherman KS, Slutsky JR. Chapter 19 - the role of comparative effectiveness research. In: Principles and Practice of Clinical Research (Fourth Edition). edn. Edited by Gallin JI, Ognibene FP, Johnson LL. Boston: Academic Press; 2018: 269\u2009\u2013\u200992.","DOI":"10.1016\/B978-0-12-849905-4.00019-8"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-20951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-20951-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-20951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T09:19:56Z","timestamp":1736932796000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-20951-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20951"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-20951-6","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study, including the patient consent process, has been approved by the Medical Ethics Committee at Nantong University (Ethical Approval-2021070) and conforms to the ethical guidelines of the Declaration of Helsinki. Informed, written consent was obtained from all individual participants in the study. The written informed consent has also been approved by the Medical Ethics Committee at Nantong University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}